Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007
Capsular group X N. meningitidis (MenX) has emerged as a cause of localized disease outbreaks in sub-Saharan Africa, but the human immune response following exposure to MenX antigens is poorly described. We therefore assessed the natural immunity against MenX in individuals who were living in an are...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2018
|
| _version_ | 1797094780278145024 |
|---|---|
| author | Norheim, G Mueller, JE Njanpop-Lafourcade, B-M Delrieu, I Findlow, H Borrow, R Xie, O Nagaputra, J Ramasamy, R Dold, C Tamekloe, TA Rollier, CS Watt, H Kere, AB Næss, LM Pollard, AJ |
| author_facet | Norheim, G Mueller, JE Njanpop-Lafourcade, B-M Delrieu, I Findlow, H Borrow, R Xie, O Nagaputra, J Ramasamy, R Dold, C Tamekloe, TA Rollier, CS Watt, H Kere, AB Næss, LM Pollard, AJ |
| author_sort | Norheim, G |
| collection | OXFORD |
| description | Capsular group X N. meningitidis (MenX) has emerged as a cause of localized disease outbreaks in sub-Saharan Africa, but the human immune response following exposure to MenX antigens is poorly described. We therefore assessed the natural immunity against MenX in individuals who were living in an area affected by a MenX outbreak during 2007 in Togo, West Africa. During 2009, 300 healthy individuals (100 aged 3-5 years, 100 aged 13-19 years and 100 aged 20-25 years) were included in the study, and serum responses were compared with sera from age-matched controls from the U.K. and Burkina Faso.MenX serum bactericidal antibody (SBA) was measured using rabbit complement, and antibodies against MenX polysaccharide (XPS) and outer membrane vesicles (XOMVs) were quantified by ELISA.The proportion of Togolese individuals with an SBA titer of ≥8 against the MenX strain was 29% (95% confidence interval (CI) 18-41) among those aged 3-5 years, 34% (95% CI 9-60) among those aged 13-19 years and 32% (95% CI 24-40) among those aged 20-25 years. These were significantly higher than observed in the control populations from the U.K (range 13-16%) and Burkina Faso (range 2-6%).In Togolese individuals, the concentration of serum IgG against XPS was higher among the two older age groups as compared to the youngest age group. Antibody concentrations against MenX PS correlated significantly with SBA titers. This supports further development of a MenX PS based conjugate vaccine. Further studies are needed to verify the ability of MenX PS to induce SBA in humans. |
| first_indexed | 2024-03-07T04:18:44Z |
| format | Journal article |
| id | oxford-uuid:ca4bb2ed-60ab-45e1-82e1-c772ca1d3939 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:18:44Z |
| publishDate | 2018 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:ca4bb2ed-60ab-45e1-82e1-c772ca1d39392022-03-27T07:06:22ZNatural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ca4bb2ed-60ab-45e1-82e1-c772ca1d3939EnglishSymplectic Elements at OxfordElsevier2018Norheim, GMueller, JENjanpop-Lafourcade, B-MDelrieu, IFindlow, HBorrow, RXie, ONagaputra, JRamasamy, RDold, CTamekloe, TARollier, CSWatt, HKere, ABNæss, LMPollard, AJCapsular group X N. meningitidis (MenX) has emerged as a cause of localized disease outbreaks in sub-Saharan Africa, but the human immune response following exposure to MenX antigens is poorly described. We therefore assessed the natural immunity against MenX in individuals who were living in an area affected by a MenX outbreak during 2007 in Togo, West Africa. During 2009, 300 healthy individuals (100 aged 3-5 years, 100 aged 13-19 years and 100 aged 20-25 years) were included in the study, and serum responses were compared with sera from age-matched controls from the U.K. and Burkina Faso.MenX serum bactericidal antibody (SBA) was measured using rabbit complement, and antibodies against MenX polysaccharide (XPS) and outer membrane vesicles (XOMVs) were quantified by ELISA.The proportion of Togolese individuals with an SBA titer of ≥8 against the MenX strain was 29% (95% confidence interval (CI) 18-41) among those aged 3-5 years, 34% (95% CI 9-60) among those aged 13-19 years and 32% (95% CI 24-40) among those aged 20-25 years. These were significantly higher than observed in the control populations from the U.K (range 13-16%) and Burkina Faso (range 2-6%).In Togolese individuals, the concentration of serum IgG against XPS was higher among the two older age groups as compared to the youngest age group. Antibody concentrations against MenX PS correlated significantly with SBA titers. This supports further development of a MenX PS based conjugate vaccine. Further studies are needed to verify the ability of MenX PS to induce SBA in humans. |
| spellingShingle | Norheim, G Mueller, JE Njanpop-Lafourcade, B-M Delrieu, I Findlow, H Borrow, R Xie, O Nagaputra, J Ramasamy, R Dold, C Tamekloe, TA Rollier, CS Watt, H Kere, AB Næss, LM Pollard, AJ Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007 |
| title | Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007 |
| title_full | Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007 |
| title_fullStr | Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007 |
| title_full_unstemmed | Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007 |
| title_short | Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007 |
| title_sort | natural immunity against capsular group x n meningitidis following an outbreak in togo 2007 |
| work_keys_str_mv | AT norheimg naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 AT muellerje naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 AT njanpoplafourcadebm naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 AT delrieui naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 AT findlowh naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 AT borrowr naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 AT xieo naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 AT nagaputraj naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 AT ramasamyr naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 AT doldc naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 AT tamekloeta naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 AT rolliercs naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 AT watth naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 AT kereab naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 AT næsslm naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 AT pollardaj naturalimmunityagainstcapsulargroupxnmeningitidisfollowinganoutbreakintogo2007 |